Skip to main content

Table 6 Virally-induced cancers subject to control by vaccines.

From: Progress and controversies in developing cancer vaccines

Cancer histology Etiologic virus Vaccine strategy Current use Clinical value
Hepatoma Hepatitis B Protein subunit vaccine In common use for high-risk populations. Protection against Hepatitis B infection is prolonged after three vaccines. Worldwide protection against hepatoma may have dramatic impact.
Cervical adenocarcinoma Human Papilloma Virus Viral and other vaccines against E6 and E7 Strong evidence for efficacy in certain populations Likely will protect against cancer, especially for patients without access to Pap smears
Burkitt's lymphoma, Nasopharyngeal cancer Epstein-Barr Virus Some T cell antigens identified Vaccines would have to be administered very early in life Untested.